VNUS Medical Technologies (VNUS) Beats the Street Earnings Estimates; Guides Above the Street
More News related to VNUS
- Roth Capital Downgrades VNUS Medical Technologies (VNUS) to Hold
- William Blair Downgrades VNUS Medical (VNUS) to Market Perform
- Notable Mergers and Acquisitions of the Day 5/8: COV/VNUS
- Morning Movers 5/8: FTWR, RDNT, VNUS, AXL, FITB, LEAP Higher; DPTR, CROX, INAP, HUN, GNW Lower
- Covidien (COV) To Acquire VNUS Medical (VNUS) For $29/Share
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
VNUS Medical Technologies (Nasdaq: VNUS) reports Q4 EPS of $0.05, 14 cents better than the analyst estimate of ($0.09). Revenues for the quarter were $20.6 million, versus the consensus of $18.37 million.
Sees FY08 EPS of $0.19 to $0.24, versus the consensus of $0.05.
VNUS Medical Technologies, Inc. provides medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition, which is the underlying cause of painful varicose veins.
Related Categories
EarningsGuidance
Hot List
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
